GLP-1s have quickly become a cornerstone of obesity and metabolic care — but the real challenge isn’t whether they work, it’s how the healthcare system uses them. Leaders are grappling with tough questions around hype, access, safety, cost, and long-term sustainability.
In this episode, recorded live at the 2025 HLTH conference, Rae Woods moderates a candid conversation with four physician leaders:
Angela Fitch, MD: Co-founder and Chief Medical Officer at KnownwellFlorencia Halperin, MD: Chief Medical Officer at Form HealthSpencer Nadolsky, MD: CEO and Founder of VineyardNathan Wood, MD: Director of Culinary Medicine at YaleDrawing from frontline clinical experience and emerging data, the panel explores why medication only approaches fall short, how wraparound care improves outcomes and adherence, and what it will take for GLP 1s to deliver true value for patients, employers, and payers.
Ep. 229: Live from HLTH: What Can’t GLP-1s Do?Ep. 248: Drugs, surgeries, and shortages: the state of obesity care in 2025Ep. 222: It's not just GLP-1s; here's what comprehensive weight management looks likeEp. 279: ‘Food as medicine’: What it is, why it matters, and how to do it right5 trends shaping pharma strategy for 2026 (and how to adapt)Innovative solutions to today’s obesity care challengesFrom reactive to proactive care: 4 key takeaways about today's COVID-19 landscape
A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.